inmagene-biopharmaceuticals-secures-21-million-in-series-b-funding

By Akshay Kedari  | Date: 2020-11-09

inmagene-biopharmaceuticals-secures-21-million-in-series-b-funding

Inmagene Biopharmaceuticals, a Chinese pharmaceutical company, has recently revealed that it has logged US$21 million from its Series B funding round which was led by Vertex Ventures China. Reportedly, the funding saw co-investment from investors like Kunlun Capital, Panacea Venture, and SCVC.

As per sources, the capital will be utilized for research and development, product in-licensing activities and global clinical trials. As of this date, Inmagene has managed to raise more than $40 million from fundraising. The company is a prominent drug developer that specializes in immunology-related therapeutic regions.

Inmagene’s management team is deeply rooted in China and has a strong global experience. Its pipeline is strengthened by two prospects- the first being its in-licenses clinical-stage foreign therapeutics that suits China, while the second being its strategic relations with global players along with whom it conducts wide-scale multi-center clinical trials.

It is worth noting that Inmagene leverages China's cost-efficient resources to create best-in-class drugs at an affordable price point. Moreover, it has commenced four new innovative programs for validated drug targets.

Speaking on the move, Dr. Jonathan Wang, CEO and Chairman, Inmagene, said that the company is grateful to Panacea, Vertex, SCVC and Kunlun along with other investors for providing strong support. This financing will help the firm strengthen its leading position in China’s immunology drug development space.

Mr. Tay Choon Chong, Managing Partner, Vertex Ventures China, commented that the organization is delighted to be a part of Inmagene's Series B funding round as its lead investor. The development of immunology-related therapeutics still remains as a 'blue ocean' in China.

Mr. Chong added that Inmagene has made some early breakthroughs in the field of immunology and has managed to develop a strong R&D pipeline. Vertex believes that with a broad global vision and robust innovative capabilities, Inmagene has the potential to develop more competitive products at a global scale to satisfy patients' needs.

Source Credit: https://www.pharmiweb.com/press-release/2020-11-09/inmagene-biopharmaceuticals-closed-21-million-series-b-financing-making-the-total-raised-to-date-o

About Author

Akshay Kedari     aeresearch.net

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More >>

More News By Akshay Kedari

Bayer sells environmental science biz to Indian firm for $13.5 million

Bayer sells environmental science biz to Indian firm for $13.5 million

By Akshay Kedari

German multinational pharmaceutical and biotechnology company, Bayer CropScience recently stated that its board has given the go-ahead for selling its Environmental Science Business to 2022 ES Discovery India, a private Indian company. The deal wi...

Stockly to raise another $12M to expand its operations & employee base

Stockly to raise another $12M to expand its operations & employee base

By Akshay Kedari

French-based software startup, Stockly is reportedly raising another $12 million (€12 million) in a Series A round from Daphni, Eurazeo, and several other business angels. Apparently, the firm pools together the inventory of several e-commerc...

Alipay+ allies with Asian E-Wallets to boost cashless travel in South Korea

Alipay+ allies with Asian E-Wallets to boost cashless travel in South Korea

By Akshay Kedari

Amidst rising efforts for promoting cashless travel, prominent mobile payment providers in Asia have recently announced an integration of the cross-border digitalized payment solutions from Alipay+ in South Korea. With this move, users of e-wallet...

Seracle, Sumsub partner for offering enhanced KYC protocols and cybersecurity

Seracle, Sumsub partner for offering enhanced KYC protocols and cybersecurity

By Akshay Kedari

Sumsub will assist Seracle in building an innovative blockchain ecosystem Sumsub will offer enhanced security to Seracle at a time when losses due to cryptocurrency thefts have increased by about 60% to $1.9 billion Seracle, a global blockc...

CATL unveils new Module to Bracket tech for heavy-duty electric trucks

CATL unveils new Module to Bracket tech for heavy-duty electric trucks

By Akshay Kedari

CATL, a Chinese battery manufacturer and technology company, has reportedly introduced a new battery technology known as Module to Bracket (MTB) for heavy-duty electric trucks. As per reliable sources, the MTB technology deploys the battery module...